84 results about "Gln - Glutamine" patented technology

The invention discloses a composite inducer for promoting adhesion and metamorphosis of marine bivalve mollusk larvae and an application method of the composite inducer. The composite inducer for promoting adhesion and metamorphosis of the marine bivalve mollusk larvae comprises glutamine, glutamic acid, potassium chloride, calcium chloride and taurine, and the concentration ratio of the glutamine to the glutamic acid to the potassium chloride to the calcium chloride to the taurine is 1: 1: 2 * 10: 1.7 * 10: 4. According to the application, glutamine, potassium ions, calcium ions, glutamic acid and taurine are matched, the application effect of the glutamine, the potassium ions, the calcium ions, the glutamic acid and the taurine in the aspect of improving the attachment and metamorphosis rate of the shellfish larvae is defined, the technical blank of multi-component cooperative regulation and control of the attachment and metamorphosis of the shellfish at present is filled, a new solution is provided for bivalve shellfish fry production, and the application prospect is wide. The method is of great significance in promoting healthy development of the mariculture industry.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of (i) glycine at position 13 with aspartic acid or (ii) glutamine at position 61 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention relates to the technical field of semen preservative preparation, in particular to a diluent preparation capable of prolonging the normal-temperature survival time of boar semen and a preparation method of the diluent preparation. Glucose, L-glutamine, an antioxidant and polysaccharide components are scientifically proportioned, and an innovative polyethyleneimine-polysaccharide copolymer is combined, so that the normal-temperature survival time of boar semen is prolonged; the dual effects of sperm metabolism regulation and cell membrane protection are realized. The polyethyleneimine-polysaccharide copolymer enhances the biocompatibility and protective ability of the diluent through stable cross-linking of amino and carboxyl, and effectively relieves the problem of sudden change of osmotic pressure and acidity of the traditional preservative. In the formula, antioxidant components, such as reduced glutathione, vitamin E and coenzyme Q10, synergistically reduce oxidative stress and delay sperm senescence. According to the whole formula, proper pH and osmotic pressure are guaranteed, the sperm motility and survival time are remarkably prolonged, the requirement of pig industry for long-term preservation of sperm is met, and the feed additive has remarkable application value and popularization potential.

This invention discloses a cyclic lipopeptide delivery system, comprising a cyclic lipopeptide carrier and nucleic acid; the head of the cyclic lipopeptide carrier is composed of heptapeptides R1R2R2R3R4R2R2 linked together by amide bonds to form a ring, and the hydrophobic tail of the cyclic lipopeptide carrier is composed of a fatty acid with a carbon chain length of 6-44 forming an ester bond with the hydroxyl group on the head amino acid R3, with the following general structural formula: where R1 is a basic amino acid, including one of histidine (His), lysine (Lys), or arginine (Arg); R2 is a hydrophobic amino acid, including one of leucine (Leu), isoleucine (Ile), or valine (Val); R3 is a hydrophilic amino acid, including one of tyrosine (Tyr), serine (Ser), or threonine (Thr); R4 is one of glutamate (Glu) or glutamine (Gln); n is an integer from 5 to 43; the cyclic lipopeptide carrier encapsulates the nucleic acid drug to form cyclic lipopeptide-nucleic acid nanoparticles.

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —[CH2]n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.

Disclosed are azotomycin prodrugs their use in treating diseases, disorders, or conditions associated with excess and / or aberrant glutamine utilization, including cancer.

Modified bacteria that produce glutamine are provided wherein a heterologous polynucleotide of glutamine export protein (rarD) and a modification that increases glutamine synthase glnA activity are included in the genome as compared to the pre-modified bacteria. In addition, methods of producing glutamine using the modified bacteria are also provided.

The application discloses a novel double-carrier expression system for protein expression and a construction method and application thereof. The novel double-carrier expression system for protein expression comprises a first carrier containing a nucleotide sequence for coding a first functional domain of glutamine synthetase and a nucleotide sequence of light chain and heavy chain of a protein to be expressed; and a second carrier containing a nucleotide sequence for coding a second functional domain of glutamine synthetase and a nucleotide sequence of a ScFv sequence of the protein to be expressed, and an amino acid sequence of the glutamine synthetase is composed of the first functional domain and the second functional domain. By using the expression system, the transfection efficiency and screening efficiency are greatly improved, and the expression amount of the target protein is obviously increased.

The invention discloses a multi-copper oxidase mutant sourced from Psychrobacter sp. And capable of efficiently degrading biogenic amine and application of the multi-copper oxidase mutant. According to the multi-copper oxidase mutant, the 183rd site of an amino acid sequence shown in SEQ ID NO.1 is mutated into histidine from phenylalanine, the 221st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into aspartic acid from asparagine, the 261st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into glutamic acid from glutamine, and the 292nd site of the amino acid sequence shown in SEQ ID NO.2 is mutated into arginine from lysine. Compared with wild type multi-copper oxidase, the multi-copper oxidase mutant disclosed by the invention has a good degradation effect on tryptamine, phenylethylamine, putrescine, cadaverine, histamine, tyramine, spermidine and spermine, and the degradation rate on the spermidine and the spermine is increased to 100%, so that the multi-copper oxidase mutant has a good application prospect in food fermentation safety production.

The invention discloses a genetically engineered bacterium for synthesizing L-glutamine by taking glucose as a carbon source and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as a chassis strain; according to the invention, a citrate synthase gene gltA, an aconitic acid hydratase gene can, an isocitrate dehydrogenase gene icd, a glutamate dehydrogenase gene gdh, a glutamine synthetase gene glnA and ammonium transporter genes amt and amtb can be overexpressed. Compared with the prior art, the invention provides a new strain and a new method for biosynthesizing L-glutamine, and the new strain and the new method have the significances of economy, scientificity, low cost, simple process and large-scale production.

The invention belongs to the technical field of gene therapy and biological medicine, and particularly provides application of leucine in preparation of a medicine for preventing and / or treating aortic aneurysm. The leucine is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

1. Name of the designed product: packing bottle (glutamine powder). 2. Use of the designed product: the designed product is used for packing health-care food. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The invention belongs to the technical field of disease diagnosis and molecular biology, and relates to application of glutamine and MKRN3 protein lysine-glutamine modification in central precocious puberty detection. Specifically, it is found for the first time that abnormal rising of the serum Gln level of a central precocious puberty child patient is remarkably related to MKRN3 protein K-Gln modification, a binary logistic regression equation is established through the content of metabolite Gln in serum and the content of MKRN3-K-Gln in serum, the diagnosis efficiency of a single-index prediction model is improved, and experiments prove that the established diagnosis model is high in accuracy and good in sensitivity, and has good clinical application prospects. The method has the potential to become an effective tool for early prediction of CPP, and the subject compliance is high, so that the method has good practical application value.

The invention relates to an I-type inulin glycosyl transferase mutant as well as a preparation method and application thereof. According to the mutant, glutamine at the 69th site of the I-type inulin glycosyl transferase with the amino acid sequence shown as SEQ ID NO.2 is mutated into isoleucine, alanine at the 254th site of the I-type inulin glycosyl transferase is mutated into serine, lysine at the 310th site of the I-type inulin glycosyl transferase is mutated into glycine, and the I-type inulin glycosyl transferase with the amino acid sequence shown as SEQ ID NO.2 is mutated into glycine. The amino acid sequence of the mutant is as shown in SEQ ID NO.4, and the mutant is named as Q69I / A254S / K310G. The enzyme activity of the mutant prepared by the invention is improved by 32% under the optimal catalytic condition, and the mutant has important research value for industrial application of industrial preparation of difructose anhydride I and I-type inulin glycosyl transferase.

The present invention relates to a strain which has increased glutamine productivity due to being transformed with a vector containing a nucleotide sequence that encodes a glutamine synthetase consisting of the amino acid sequence of SEQ ID NO: 1.

The invention discloses an H9N2 influenza virus M1 protein mutant and application thereof, and belongs to the technical field of biology. The H9N2 influenza virus M1 protein mutant is a protein obtained by mutating histidine H at the 222 position of an amino acid sequence of H9N2 influenza virus M1 protein into glutamine Q and keeping other amino acid residues unchanged, and the amino acid sequence of the H9N2 influenza virus M1 protein mutant is as shown in SEQ ID NO. 1. After a mouse is infected with the M1-H2222Q point mutation recombinant virus obtained by a reverse genetics technology, the weight loss of the mouse is obvious, the replication ability of the virus in the lung of the mouse is enhanced, and the pathological change is obvious. The M1 protein mutant disclosed by the invention can be used for rapidly obtaining the mouse adaptive H9N2 influenza virus.

The application discloses citrullinated collagen type II polypeptide and application thereof. The amino acid sequence of the polypeptide is Ste-QYMCitADQAAGGLR (SEQ ID NO. 1), wherein the N terminal of glutamine Q in the sequence is connected with octadecanoic acid Ste, and the fourth position in the sequence is modified by citrullination. The citrullinated collagen type II polypeptide has a long drug half-life, can effectively treat rheumatoid arthritis, and has small side effects.

The invention provides application of a GPX1 inhibitor combined with a copper death inducer in preparation of a cold tumor treatment medicine. The key node effect of GPX1 in cold tumor metabolism reprogramming is found and utilized. In a cold tumor microenvironment deficient in glutamine, tumor cells often resist a copper death inducer. Through targeted inhibition of GPX1, the sensitivity of cold tumor cells to copper ion toxicity is significantly enhanced, and the drug resistance problem caused by metabolic pressure is effectively overcome.

The application discloses an engineered nitrile hydratase and application thereof. The engineered nitrile hydratase is based on a wild-type nitrile hydratase and comprises a random coil domain located near an active center and having a sequence of SEQ ID NO. 1, wherein methionine in the random coil domain is replaced by any one of glycine, leucine, isoleucine, glutamine, threonine, glutamic acid, arginine and lysine. The engineered nitrile hydratase with any one of the above mutations has higher enzyme activity and improves catalytic efficiency.

An object of the present application is to provide a new composition for promoting ketogenesis. According to the present application, there is provided a composition for promoting ketogenesis containing one or two or more amino acids selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition of the present application can further contain either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

This disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof which have uses in vaccination methods or therapeutic strategies. In certain embodiments, this disclosure relates to modified HIV envelope proteins or envelope protein fragments, or trimeric complexes thereof, comprising an arginine (R) at position 166, glutamine (Q) at position 170, and an amino acid histidine (H) at position 173. In certain embodiments, this disclosure relates to nucleic acids and recombinant vectors encoding said proteins.

The invention discloses escherichia coli for enhancing expression of glutamine synthase and application of the escherichia coli in production of L-tryptophan. The invention provides recombinant escherichia coli. The recombinant escherichia coli comprises glutamine synthase for expressing a bacillus subtilis source. According to the invention, a glutamine synthase coding gene glnA which is derived from B.subtilis and optimized by a codon is expressed in receptor escherichia coli, and an L-tryptophan fermentation production strain with more cost benefits can be produced. The method disclosed by the invention is of great significance for improving the fermentation yield of the L-tryptophan.

The application discloses application of glutamine ethyl indole in promoting biological rhythm gene expression. The application also provides a recovery agent for biological rhythm gene expression, which comprises glutamine ethyl indole. The application further provides application of the recovery agent for biological rhythm gene expression in skin care products and cosmetics and the skin care products and cosmetics. The recovery agent for biological rhythm gene expression of the application comprises glutamine ethyl indole, can restore the expression of CLOCK gene and Per3 gene to a normal stable level, helps to restore a normal cycle of rhythm, and provides a new skin care idea for biological rhythm cosmetics / skin care products.

This invention discloses a method for constructing a Brca2-p.Q462Ter genetically engineered mouse and its application. The Brca2 genetically engineered mouse provided by this invention carries a truncated mutation in its Brca2 gene. This mutation is located at exon 10 of the mouse Brca2-201 transcript, changing amino acid position 462 from glutamine Q (Gln) to the stop codon Ter, forming the Brca2-p.Q462Ter mutation. The Brca2-p.Q462Ter genetically engineered mouse is used to simulate the human BRCA2 gene truncated mutation p.Gln472Ter, c.1414C>T. Amino acid homology analysis shows that the mouse BRCA2 protein Q462 site is homologous to the human BRCA2 protein Q472 site; therefore, this mouse mutation site can be used to simulate the corresponding truncated mutation effect in human BRCA2. This genetically engineered mouse can simulate, at the whole animal level, the abnormal DNA damage repair, impaired homologous recombination repair function, decreased genome stability, and susceptibility to related diseases caused by BRCA2 truncated mutations, thus providing a reliable tool for research on BRCA2-related pathogenesis, developmental effects, drug screening, and efficacy evaluation.

The application discloses a broad-spectrum affinity peptide ligand for influenza vaccine separation and purification and application thereof. The broad-spectrum affinity peptide ligand contains an amino acid sequence which is combined with the conserved structural units 130-loop, 150-loop and 190-helix of the hemagglutinin receptor binding site of an influenza virus, and the amino acid sequence is R 1 -R 2 -R 3 -(R 4 )3-R 5 -(R 4 )2-R 6 -R 7 -R 8 , R 1 is any one of glutamic acid, arginine, histidine and proline, R 2 is tryptophan, R 3 is any one of tyrosine and phenylalanine, R 4 is glycine, R 5 is any one of tryptophan, tyrosine and phenylalanine, R 6 is any one of glutamic acid, histidine, glutamine and tyrosine, R 7 is any one of tryptophan and phenylalanine, and R 8 is proline. The broad-spectrum affinity peptide ligand has high broad-spectrum affinity, and the broad-spectrum affinity chromatography medium can obtain the influenza vaccine with high purity and yield, and has great potential in application to the separation and purification process of the influenza vaccine.

Prodrugs of glutamine analogs are disclosed, such as the prodrugs of aza-serine and 6-diazo-5-oxo-norleucine (DON) and 5-diazo-4-oxo-L-norvaline (L-DONV).

This application relates to the field of metabolic engineering and genetic engineering technology for production, specifically providing a uracil-producing strain, its construction method, and its application. This strain is... E. coli Knockout of the uridine kinase gene in the W3110 genome udk Simultaneously integrates the T7 RNA polymerase gene; weakens the uridine kinase gene. pyrH Overexpression of carbamoyl phosphate synthase gene carAB ribose-phosphokinase gene prsA pyrimidine-5'-nucleotide nuclease gene ppnN UMP phosphohydrolase gene umpH and umpG Ribonucleotide hydrolase 1 gene rihA and glutamine synthase gene glnA Heterogeneous introduction of wild-type Bacillus subtilis B. subtilis 168 orotate nucleoside monophosphate decarboxylase gene pyrF and orotic acid ribosyltransferase gene pyrE To achieve safe, efficient, and low-cost production of uracil.

The invention discloses an encapsulated oil-in-water type composition and a preparation method thereof. The encapsulated oil-in-water type composition comprises the following components in percentage by weight: 0.1-1% of retinol; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; 10%-20% of an oil component, wherein the oil component comprises caprylic acid / capric triglyceride; 0.1%-5% of a rheology modifier; 5-20% of a humectant; and the balance of water. The capsule product has good slow release property. According to the composition disclosed by the invention, high-content addition and high-efficacy performance of the retinol are realized, meanwhile, good formula stability can also be realized, and the problem of skin irritation caused by the retinol is improved.

The invention belongs to the technical field of biological medicines, and discloses an endometrial organ and a construction method thereof. The invention provides a construction method of endometrial organs. An IM differential culture medium 1 containing L-alanyl-L-glutamine with specific concentration and CHIR 99021, an IM differential culture medium 2 containing L-alanyl-L-glutamine with specific concentration, bFGF and RA and an MD differential culture medium containing CHIR 99021 with specific concentration are adopted as a Miller tube cell induced differentiation culture system; the method can efficiently guide the differentiation of the human pluripotent stem cells to the Mullerian canal cells while maintaining the cell proliferation ability, the obtained Mullerian canal cells have excellent proliferation and differentiation ability, and an organoid with natural endometrial characteristics can be formed in an endometrial organoid induced differentiation culture system; the material can be used as an experimental material in research on development mechanism of endometrium, disease model establishment, drug screening and the like, and has a wide application prospect.

The present invention relates to cells expressing chimeric antigen receptors against BCMA and a glutamine transporter, and uses thereof in the treatment of cancer or autoimmune diseases. The invention also relates to a method for the prognosis of multiple myeloma in a subject.